Takeda Pharmaceutical (NYSE:TAK) Earns Overweight Rating from Analysts at Morgan Stanley

Morgan Stanley initiated coverage on shares of Takeda Pharmaceutical (NYSE:TAK) in a report published on Tuesday morning. The brokerage issued an overweight rating on the stock.

Separately, Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Performance

Takeda Pharmaceutical stock opened at $16.31 on Tuesday. Takeda Pharmaceutical has a fifty-two week low of $12.80 and a fifty-two week high of $16.48. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.76 and a current ratio of 1.37. The stock has a market cap of $51.91 billion, a P/E ratio of 203.93 and a beta of 0.03. The firm’s fifty day moving average price is $14.88 and its 200-day moving average price is $14.71.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, October 30th. The company reported $0.44 EPS for the quarter, meeting analysts’ consensus estimates of $0.44. Takeda Pharmaceutical had a return on equity of 10.32% and a net margin of 0.86%.The business had revenue of $7.30 billion for the quarter, compared to analysts’ expectations of $8.01 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. On average, equities research analysts expect that Takeda Pharmaceutical will post 1.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of large investors have recently bought and sold shares of TAK. SG Americas Securities LLC boosted its stake in shares of Takeda Pharmaceutical by 81.5% during the fourth quarter. SG Americas Securities LLC now owns 13,856 shares of the company’s stock valued at $216,000 after purchasing an additional 6,222 shares during the period. Park Avenue Securities LLC raised its holdings in Takeda Pharmaceutical by 14.1% during the 4th quarter. Park Avenue Securities LLC now owns 37,684 shares of the company’s stock valued at $587,000 after buying an additional 4,662 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Takeda Pharmaceutical by 37.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 247,529 shares of the company’s stock valued at $3,624,000 after buying an additional 67,770 shares during the period. Allworth Financial LP grew its holdings in Takeda Pharmaceutical by 8.3% in the 3rd quarter. Allworth Financial LP now owns 12,305 shares of the company’s stock worth $180,000 after acquiring an additional 948 shares during the last quarter. Finally, First Affirmative Financial Network increased its position in shares of Takeda Pharmaceutical by 16.8% in the third quarter. First Affirmative Financial Network now owns 41,852 shares of the company’s stock valued at $613,000 after acquiring an additional 6,025 shares during the period. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.